Skip to main content

Advertisement

Table 1 Experimental cytotoxic activity of triazoles 132 against four cancer cell lines

From: Discovery of novel 1,2,3-triazole derivatives as anticancer agents using QSAR and in silico structural modification

Compound IC50 (μM)
HuCCA-1 HepG2 A549 MOLT-3
1 8.65 ± 1.70b 9.07 ± 1.15b 34.54 ± 0.89c Inactived
2 Inactived 57.54 ± 8.66c Inactived Inactived
3 Inactived 28.21 ± 2.89c Inactived 74.23 ± 5.08c
4 Inactived 81.75 ± 2.89c Inactived Inactived
5 87.89 ± 0.92c 100.54 ± 2.12c Inactived 32.02 ± 0.76c
6 Inactived Inactived Inactived 61.42 ± 1.01c
7 Inactived 41.62 ± 1.15c Inactived 34.24 ± 3.11c
8 Inactived 49.40 ± 4.04c Inactived 8.81 ± 0.42b
9 Inactived 57.52 ± 6.51c 79.18 ± 14.15c 9.22 ± 0.48b
10 Inactived 34.51 ± 4.36c 39.04 ± 0.37c 10.33 ± 0.08c
11 16.12 ± 0.71c 12.44 ± 1.71c 19.60 ± 2.33c 88.97 ± 3.42c
12 Inactived Inactived Inactived 10.65 ± 0.48c
13 Inactived 23.89 ± 3.00c 18.19 ± 0.35c 60.99 ± 6.66c
14 Inactived Inactived 28.03 ± 1.63c 17.43 ± 0.41c
15 Inactived Inactived Inactived 10.10 ± 0.27c
16 51.35 ± 5.66c Inactived Inactived Inactived
17 Inactived 6.50 ± 0.14b Inactived Inactived
18 Inactived 60.48 ± 14.14c Inactived Inactived
19 Inactived Inactived 66.30 ± 0.70c Inactived
20 30.16 ± 4.07c 19.12 ± 3.06c 14.90 ± 1.02c 21.86 ± 3.67c
21 0.63 ± 0.04a,e 12.36 ± 1.97c 0.57 ± 0.02a,e 18.63 ± 1.62c
22 Inactived 5.27 ± 0.71b 59.07 ± 11.31c Inactived
23 24.80 ± 2.19c Inactived 25.29 ± 10.78c 80.78 ± 10.23c
24 72.0 ± 10.54c 31.79 ± 2.89c 41.04 ± 9.40c Inactived
25 Inactived 2.57 ± 0.99b Inactived Inactived
26 Inactived 1.26 ± 0.42b Inactived 36.35 ± 1.36c
27 39.71 ± 1.48c 1.48 ± 0.61b 27.21 ± 1.77c Inactived
28 inactived 0.56 ± 0.01a,e Inactived Inactived
29 4.79 ± 0.28b 3.37 ± 0.96b 8.43 ± 2.79b 11.74 ± 4.97c
30 31.09 ± 8.91c 12.49 ± 2.47c 31.84 ± 8.13c 34.12 ± 0.97c
31 76.15 ± 1.77c 41.36 ± 2.89c 31.91 ± 9.76c 5.82 ± 0.85b
32 39.98 ± 4.03c Inactived Inactived 5.50 ± 0.61b,e
Etoposidef g 30.16 ± 0.50 g 0.051 ± 0.002
Doxorubixinf 0.83 ± 0.07 0.79 ± 0.08 0.44 ± 0.01 g
  1. The compounds (132) were classified by their IC50 values into four classes i.e., highly active (IC50 < 1 µM), moderately active (1 µM < IC50 < 10 µM), weakly active (IC50 > 10 µM) (Pérez-Sacau et al. 2007) and inactive (IC50 > 50 µg/mL) (Prachayasittikul et al. 2014). All inactive compounds were excluded from the QSAR analysis. Four QSAR models were separately constructed based on experimental testing against four cancer cell lines
  2. aHighly active compound
  3. bModerately active compound
  4. cWeakly active compound
  5. dInactive compound
  6. eThe most potent compound against each cell line
  7. fReference drugs
  8. gNot tested